News | Digital Pathology | July 24, 2023

Pathology market’s first algorithm to use additive multiple instance learning (aMIL) heatmaps to provide greater transparency for how AI predictions are made 

Pathology market’s first algorithm to use additive multiple instance learning (aMIL) heatmaps to provide greater transparency for how AI predictions are made

July 24, 2023 —  PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, today announced the availability of AIM-HER2 Breast Cancer [i] for research use by clinical laboratories, researchers, and drug developers. AIM-HER2 Breast Cancer delivers automated digital HER2 scoring and is the market’s first algorithm to use additive multiple instance learning (aMIL) heatmaps to visualize the slide features driving the algorithm’s predicted score. AIM-HER2 will be available to biopharma researchers and clinical research lab pathologists on PathAI’s AISight [i] digital pathology platform in both the clinical research lab and clinical trial setting. 

“HER2 IHC assays have provided immense impact to patients by allowing for a widely available test to establish drug eligibility,” said Mike Montalto, Chief Scientific Officer at PathAI. “With AIM-HER2 Breast Cancer, we at PathAI sought to build upon the success of HER2 testing by assisting pathologists in their ability to more confidently score HER2, especially in borderline cases that can be the most challenging and time consuming to review. We also look forward to partnering with drug developers who may be interested in enhancing the scoring of the more recently described HER2 low assay as an important emerging patient population.” 

In addition to predicting slide-level HER2 score, AIM-HER2 Breast Cancer’s visualizations on AISight utilize additive multiple instance learning (aMIL) heatmaps to deliver a more interpretable and explainable prediction, diminishing the ‘black box’ challenges typically associated with understanding how AI predictions are made. 

“Our interpretable heatmaps are critical to driving utilization and adoption of AI – because it’s not about blind trust,” said Eric Walk, Chief Medical Officer at PathAI. “The results can be interpreted, explained – and confirmed – by humans. It also streamlines workflow as it allows pathologists to hone in on specific features to confirm the algorithm score and output vs. needing to analyze the entire slide.” 

AIM-HER2 Breast Cancer was developed using 157,000 tissue annotations and consensus scores on a dataset of over 4,000 slides (collected from more than 65 expert breast pathologists). In addition to slide-level HER2 scoring, AIM-HER2 Breast Cancer quantifies invasive carcinoma and provides a comprehensive analysis of the entire WSI without necessitating manual selection of the region of interest (ROI). 

For more information: www.PathAI.com 

 

Footnote 

[i] Both AISight and the AIM-HER2  

Breast Cancer Algorithm  

are intended for research-use only. Not for use in diagnostic procedures. 


Related Content

News | Mammography

September 22, 2023 — Hologic Inc. and Bayer announced an international partnership to deliver contrast-enhanced ...

Time September 22, 2023
arrow
News | Digital Pathology

September 22, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...

Time September 22, 2023
arrow
Feature | Breast Imaging | By Susan Harvey, MD, FSBI

In countries with organized screening programs, regular breast cancer screening has been a crucial tool in the clinician ...

Time September 22, 2023
arrow
Feature | Artificial Intelligence | By Melinda Taschetta-Millane

Jesse Ehrenfeld, MD, MPh, FAMIA, FASA, FCPP, president of the American Medical Association (AMA), addressed the topic of ...

Time September 22, 2023
arrow
Feature | Ultrasound Imaging | By Mustafa Hassan, PhD

Handheld ultrasound has not yet reached mainstream adoption, but the market is still forecast to reach over $500 million ...

Time September 20, 2023
arrow
News | Artificial Intelligence

September 20, 2023 — Medical imaging artificial intelligence (AI) company Annalise.ai has announced that the results ...

Time September 20, 2023
arrow
News | Information Technology

September 18, 2023 — Healthcare organizations across the world are working with poor data. In fact, while high-quality ...

Time September 18, 2023
arrow
News | Ultrasound Imaging

September 15, 2023 —EchoNous, a leader in transformative handheld point-of-care ultrasound solutions, announced a new ...

Time September 15, 2023
arrow
News | FDA

September 13, 2023 — Annalise.ai, a leader in AI-powered medical imaging solutions, announced the receipt of 510(k) ...

Time September 13, 2023
arrow
News | Mammography Reporting Software

September 13, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has ...

Time September 13, 2023
arrow
Subscribe Now